Prostate cancer is the second most frequently diagnosed type of cancer and the fifth most common cause of cancer deaths in men worldwide. Treatment options for patients with advanced prostate cancer have developed rapidly in recent years. However, there is no international agreement on treatment guidelines.
Aim of the study
The aim of this project is to learn more about prostate cancer, to describe the use of the various therapies internationally and to find out whether there is a connection between the treatment sequence or combination and the survival rate. We also want to identify disease subtypes (using biomarkers - special factors that are examined on tissue) that respond particularly well or poorly to a therapy, therapy sequence or combination of therapies.Target group
Patients aged 21 and over with diagnosed advanced prostate cancer (hormone-sensitive with metastases or castration-resistant with or without metastases) who have not received systemic therapy (chemotherapy etc.) for prostate cancer within the last 2 years. - Metastatic hormone-sensitive: If you have prostate cancer that has spread to other parts of the body and you have not received hormone therapy. - Castration-resistant: If you have already been treated with hormone therapy but the cancer continues to spread even though you have a low testosterone levelProcedure
In any case, your prostate cancer treatment will proceed in the same way as if you were not part of the research project. No extra appointments are required.- Information is collected about your cancer treatment. You will be asked to complete a questionnaire every 3 months about your condition, the therapy and your experiences.
- Approximately 2 tablespoons of blood will be taken for genetic testing together with the regular blood sample at inclusion, the first change of therapy and/or the 1-year follow-up examination, as well as at each change of cancer therapy.